Patent US4259315A successfully refreshed from Google Patents.
US4259315A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release potassium dosage form
Assignee: Wyeth LLC
•
Filing: 1980-06-13
•
Granted: 1981-03-31
•
Expires: 2000-06-13
Abstract
Abstract Pharmaceutical compositions for treating potassium deficiency in monogastric animals comprising gelatin capsules containing mixture comprised of controlled release form of microencapsulated potassium salt and hydrophilic surfactant are disclosed.
Inventors
- 👤 Irwin Lippmann
- 👤 Shankar D. Popli
- 👤 Larry G. Miller
- 👤 Louis G. Bell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:08
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/14; A61K9/00; A61K9/48; A61K9/4841; A61K9/4858; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047; A61P; A61P1/00; A61P1/12; A61P3/00; A61P39/00; A61P39/02; A61P7/00; A61P7/10
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
23 words
A pharmaceutical composition comprising a gelatin capsule containing therein a mixture comprising microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt.
Claim 2
Dependent Claim
23 words
A pharmaceutical composition comprising a gelatin capsule containing therein a mixture comprising microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt.
Claim 3
Dependent Claim
32 words
A pharmaceutical composition comprising a gelatin capsule containing therein a mixture of microcapsules having an outer layer of polymeric material and core of potassium salt and hydrophilic surfactant externaul to said microcapsules.
Claim 4
Dependent Claim
32 words
A pharmaceutical composition comprising a gelatin capsule containing therein a mixture of microcapsules having an outer layer of polymeric material and core of potassium salt and hydrophilic surfactant externaul to said microcapsules.
Claim 5
Dependent Claim
34 words
The composition as defined in claim 2 where in the surfactant has a HLB number in excess of 10 and is present in an amount of from about 0.05 to 5.0 percent by weight.
Claim 6
Dependent Claim
21 words
The composition as defined in claim 3 wherein the polymeric material is ethyl cellulose and the potassium salt is potassium chloride.
Claim 7
Dependent Claim
86 words
A pharmaceutical composition for treating potassium deficiency in monogastric animals comprising a gelatin capsule containing therein a mixture comprising controlled-released microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt, said microencapsulated salt containing 3 to 50 weight percent polymeric material and said hydrophilic surfactant being present in an amount within the range of 0.05 to 5.0 weight percent based on the weight of said microencapsulated salt sufficient to increase flowability of said microencapsulated salt in a partially obstructed alimentary tract of a monogastric animal.
Claim 8
Dependent Claim
86 words
A pharmaceutical composition for treating potassium deficiency in monogastric animals comprising a gelatin capsule containing therein a mixture comprising controlled-released microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt, said microencapsulated salt containing 3 to 50 weight percent polymeric material and said hydrophilic surfactant being present in an amount within the range of 0.05 to 5.0 weight percent based on the weight of said microencapsulated salt sufficient to increase flowability of said microencapsulated salt in a partially obstructed alimentary tract of a monogastric animal.
Claim 9
Dependent Claim
27 words
A pharmaceutical composition of claim 5 wherein the surfactant is in an amount of 0.05 to 1.0 weight percent based on the weight of the microencapsulated salt.
Claim 10
Independent Claim
57 words
A method for the treatment of potassium deficiency or prevention of potassium depletion in a human which comprises administering to said human an effective amount of potassium, said potassium being administered in the form of a non-toxic pharmaceutical comprising a gelatin capsule containing a mixture comprising microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt.
Claim 11
Independent Claim
57 words
A method for the treatment of potassium deficiency or prevention of potassium depletion in a human which comprises administering to said human an effective amount of potassium, said potassium being administered in the form of a non-toxic pharmaceutical comprising a gelatin capsule containing a mixture comprising microencapsulated potassium salt and hydrophilic surfactant external to said microencapsulated salt.
Claim 12
Independent Claim
69 words
A method for the treatment of potassium depletion or prevention of potassium depletion in a human which comprises administering to said human an effective amount of potassium, said potassium being administered in the form of a non-toxic pharmaceutical composition comprising a gelatin capsule containing a mixture comprising microcapsules having an outer layer of ethyl cellulose and a core of potassium chloride and a hydrophilic surfactant external to said microcapsules.
Claim 13
Independent Claim
69 words
A method for the treatment of potassium depletion or prevention of potassium depletion in a human which comprises administering to said human an effective amount of potassium, said potassium being administered in the form of a non-toxic pharmaceutical composition comprising a gelatin capsule containing a mixture comprising microcapsules having an outer layer of ethyl cellulose and a core of potassium chloride and a hydrophilic surfactant external to said microcapsules.
Claim 14
Dependent Claim
36 words
The method as defined in claim 6 wherein the surfactant has a HLB number in excess of 10 and is present in the composition in an amount of from about 0.05 to 5.0 percent by weight.
Claim 15
Dependent Claim
21 words
The method as defined in claim 7 wherein the polymeric material is ethyl cellulose and the potassium salt is potassium chloride.
References Cited (Backward Citations)
BE817670A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-03-30 | 1984-09-29 | 1985-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-03-30 | 1988-09-29 | 1989-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-03-30 | 1992-09-29 | 1993-03-31 | $7700.00 | Window Closed / Lapsed |